NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Allay Therapeutics

Allay Therapeutics

Private
San Jose, CaliforniaHealthcare & Life Scienceshttps://www.allaytx.com/

Last Round

Debt

Jun 5, 2025

Total Funding Raised

$167.5M

Company Overview

Allay Therapeutics is a biotechnology company that develops sustained analgesic products aimed at enhancing post-surgical pain management and recovery for patients and healthcare providers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

non-opioid analgesicspain managementdrug delivery platformpost-surgical painopioid alternativesultra-sustained releasebioresorbable implantsclinical-stage biotechorthopedic pain reliefcontrolled drug releasebiopharmaceuticalnon-narcotic pain reliefdrug licensingpain tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Allay Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Allay Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Allay Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtJun 5, 2025
Series CSep 15, 2021
Series BFeb 12, 2019

Key People

Founding team and executive leadership

Adam Gridley

Chief Executive Officer

Executive Team

Allay Therapeutics Investors

Notable investors and investment history

Allay Therapeutics investors
InvestorRounds
TemasekSeries C
Vertex Ventures HCDebt, Series C
Arboretum VenturesDebt, Series C
New Enterprise Associates (NEA)Debt, Series C, Series B
Lightstone VenturesSeries B, Seed, Series A, Debt
ClavystBioDebt
EDBIDebt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 5, 2025

    $58M round completed.

  • Jun 5, 2025

    Anselm Tan of ClavystBio joins the board.

Allay Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Allay Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Allay Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Jose, California
Employee Range31
Year Founded2017
Last FundingJun 5, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.